LY364947: Selective TGF-β Type I Receptor Kinase Inhibitor for EMT and Retinal Degeneration Research

Executive Summary: LY364947 is a potent, selective inhibitor of TGF-β type I receptor kinase (IC50: 51 nM, in vitro), blocking Smad2 phosphorylation and TGF-β pathway signaling in multiple cell models (APExBIO). It suppresses epithelial-mesenchymal transition (EMT) markers, including fibronectin and vimentin, while promoting E-cadherin expression and reducing cell migration (Gu et al., 2025). In animal studies, LY364947 attenuates retinal degeneration and vascular damage induced by NMDA. The compound is DMSO-soluble (≥24.4 mg/mL), chemically stable at -20°C, and intended for scientific research only. Key limitations include insolubility in water/ethanol and non-applicability for diagnostic/therapeutic use.

Biological Rationale

The transforming growth factor-β (TGF-β) signaling pathway is a central regulator of cell proliferation, differentiation, and extracellular matrix remodeling. Dysregulation of TGF-β signaling contributes to pathological fibrosis, cancer progression, and epithelial-mesenchymal transition (EMT) in multiple tissues (Gu et al., 2025). EMT is characterized by loss of epithelial markers (e.g., E-cadherin) and gain of mesenchymal markers (e.g., vimentin, fibronectin), driving increased cell migration and invasion. Modulation of the TGF-β pathway, particularly by inhibiting the type I receptor kinase domain, is a validated strategy to suppress EMT and its downstream pathological effects (Related Article).

Mechanism of Action of LY364947

LY364947, chemically 4-(5-pyridin-2-yl-1H-pyrazol-4-yl)quinoline (MW: 272.3; C17H12N4), acts as a highly selective ATP-competitive inhibitor of the TGF-β type I receptor kinase domain. By binding the kinase domain, it prevents phosphorylation and activation of Smad2, a critical step in canonical TGF-β signaling. This blockade leads to downstream inhibition of EMT marker expression (fibronectin, vimentin) and restoration of epithelial phenotype (E-cadherin upregulation). In HOXB9-MCF10A cells, LY364947 efficiently suppresses TGF-β-dependent migration and invasion (APExBIO; Gu et al., 2025).

Evidence & Benchmarks

• LY364947 inhibits TGF-β type I receptor kinase with an IC50 of 51 nM in biochemical assays (APExBIO).
• In HOXB9-MCF10A cells, LY364947 blocks Smad2 phosphorylation and reduces mesenchymal markers, while restoring E-cadherin expression (Gu et al., 2025).
• LY364947 suppresses TGF-β–induced EMT, migration, and invasiveness in breast epithelial and cancer cell models (Gu et al., 2025).
• In rat NMDA-induced retinal injury models, LY364947 attenuates both retinal degeneration and vascular permeability/damage (APExBIO).
• LY364947 is DMSO-soluble to ≥24.4 mg/mL, insoluble in water/ethanol; stability is optimal at -20°C (APExBIO).
• Combined inhibition of TGF-β and Wnt/β-catenin pathways (using agents like LY364947 and JQ1) delivers synergistic suppression of EMT in preclinical models (Gu et al., 2025).

For a comparative review of mechanisms and translational potential, see this article, which complements the present benchmark-focused dossier by providing a systems-biology perspective.

Applications, Limits & Misconceptions

LY364947 is widely used for:

• Preclinical studies on EMT inhibition in cancer biology and fibrosis research.
• Probing TGF-β-dependent signaling in cell migration, invasion, and differentiation assays.
• Vascular and retinal degeneration models, specifically for evaluating TGF-β pathway blockade.

For protocol optimization and troubleshooting, this guide provides scenario-driven Q&A and benchmarking, extending this article by focusing on practical workflow challenges.

Common Pitfalls or Misconceptions

• LY364947 is not a therapeutic drug and should not be used in humans or animals outside research settings.
• It does not inhibit non-TGF-β kinases at relevant concentrations; off-target effects are rare but possible at high doses.
• Solubility is limited to DMSO; attempts to dissolve in water or ethanol will fail.
• LY364947 is unstable at room temperature for extended periods; always store at -20°C and use solutions promptly.
• It is not suitable for diagnostic, clinical, or in vivo therapeutic use due to regulatory and toxicological constraints.

For advanced study design and real-world decision points, this article further clarifies optimal use and pitfalls, complementing this dossier with actionable insights.

Workflow Integration & Parameters

LY364947 (SKU B2287) from APExBIO is supplied dissolved in DMSO, ensuring maximal solubility for cell-based and biochemical assays. Recommended concentrations typically range from 0.1 to 10 μM, depending on the model system and endpoint measured. For best results:

• Store powder and stock solutions at -20°C in light-protected containers.
• Prepare working solutions fresh; avoid repeated freeze-thaw cycles.
• Validate pathway inhibition by monitoring Smad2 phosphorylation status (e.g., via Western blot).
• Use appropriate vehicle controls to account for DMSO effects in cell-based assays.

For detailed protocol optimization, refer to the LY364947 product datasheet and related workflow guides.

Conclusion & Outlook

LY364947 remains a gold-standard selective TGF-β type I receptor kinase inhibitor for preclinical research on EMT, cell migration, and retinal degeneration. Its atomic, reproducible inhibition of Smad2 phosphorylation enables mechanistic dissection of TGF-β–driven processes. However, users must respect its solubility, storage, and regulatory boundaries. Future work may explore combinatorial strategies targeting TGF-β and allied pathways for improved anti-fibrotic and anti-metastatic applications (Gu et al., 2025).